PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.
Scheinberg T, Lin HM, Fitzpatrick M, Azad AA, Bonnitcha P, Davies A, Heller G, Huynh K, Mak B, Mahon K, Sullivan D, Meikle PJ, Horvath LG.
Scheinberg T, et al. Among authors: fitzpatrick m.
Prostate Cancer Prostatic Dis. 2024 Mar;27(1):136-143. doi: 10.1038/s41391-023-00666-2. Epub 2023 May 5.
Prostate Cancer Prostatic Dis. 2024.
PMID: 37147359
Free PMC article.